Statistically Significant Results for Heart Rate Variability (HRV) Indices with Judgment Variables as Covariates. by David Vagni (8060432)

Subjects:

Significant clusters: Coronal PET images showing brain regions with significant (p < 0.001 and K > 50) metabolic inhibition (A-G) and activation (H-I) in rats following cocaine sel... by Christopher Rowan (21499924)

Mean muscle activation patterns across the gait cycle during walking with mediolateral (ML) forces for <i>A)</i> able-bodied individuals and <i>B)</i> individuals after stroke duri... by Sanne Ettema (18786312)

Age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. by Xiaofeng He (2618752)

Subjects:

Age-standardized prevalence rates of gynecological diseases across 21 GBD regions, by SDI, from 1990 to 2021. by Xiaofeng He (2618752)

Subjects:

Estimated annual percentage change in age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. by Xiaofeng He (2618752)

Subjects:

Prevalence and trends of gynecological diseases (GDs) among women of childbearing age, by age group and SDI. by Xiaofeng He (2618752)

Subjects:

Estimated annual percentage changes in the prevalence rate of specific gynecological diseases from 1990 to 2021, categorized by age group and SDI. by Xiaofeng He (2618752)

Subjects:

Prevalence of gynecological diseases (GDs) among women of childbearing age in 2021, along with their changes from 1990 to 2021, and the contribution of each GD to the overall preva... by Xiaofeng He (2618752)

Subjects:

The global prevalence of gynecological diseases among women aged 15-49 years in 1990 and 2021, along with the trends and changes observed between these years. by Xiaofeng He (2618752)

Subjects:

S1 File - Utilization of psychotropic drugs in Serbia from 2006 to 2021: Patterns before and during the COVID-19 pandemic by Jelena Filimonovic (22305307)

Subjects:

Anion-Assisted Glycosylation of Galactose: A Computational Study by Kerli Tali (22769704)

Subjects:

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Effect of MGO on <i>in vitro</i> maturation and developmental competence of mouse COCs and DOs. by Shahrzad Ronasi (20933556)